Directors
Robert W. Rieder, MBA
CEO & Chairman
Mr. Rieder is Cardiome’s Chief Executive Officer and Chairman and has also previously served as Cardiome’s Vice-Chairman. He joined Cardiome in April 1998 as President and Chief Executive Officer. Mr. Rieder has extensive experience in venture capital and in operational management. Prior to joining Cardiome, Mr. Rieder was Vice-President at MDS Ventures Pacific Inc., the Vancouver-based affiliate of MDS Capital Corp., and has served as a director for nine public and private technology companies. Mr. Rieder has also acted as Chief Operating Officer for DBA Telecom Inc., and CEO for Synapse Technologies Inc. Mr. Rieder received his MBA from the University of Western Ontario.
Doug G. Janzen
President, Chief Business Officer & Director
Mr. Janzen is Cardiome’s President and Chief Business Officer. Mr. Janzen manages all of Cardiome’s business activities, including capital markets, commercial development, partnering, licensing and other strategic transactions. Mr. Janzen joined Cardiome in 2003 as Chief Financial Officer. He has been instrumental to the advancement of Cardiome’s corporate development and the strengthening of its financial position. Prior to joining Cardiome, Mr. Janzen served as Managing Director, Health Sciences and Partner at Sprott Securities, Inc., a Toronto-based investment bank.
Richard M. Glickman (3)
Lead Independent Director
Mr. Glickman was the co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Corporation. Prior to establishing Aspreva, Mr. Glickman was the co-founder and Chief Executive Officer of Stressgen Biotechnologies Corporation. Since 2000, Mr. Glickman has served as the Chairman of the board of Vigil Health Solutions Inc., a healthcare services company. Mr. Glickman was also the founder and director of Ontario Molecular Diagnostics, a diagnostic facility that evolved into the largest molecular diagnostic laboratory in Canada. He co-founded Probtec Corporation, a rational drug design and molecular genetics firm, where he established and introduced the first licensed DNA-based forensic and paternity testing services in Canada. He has served on numerous biotechnology boards including roles as Chairman of Life Sciences British Columbia (formerly the British Columbia Biotechnology Alliance), Director of the Canadian Genetic Disease Network and as a member of the federal government’s National Biotechnology Advisory Committee. Mr. Glickman received the Ernst & Young Entrepreneur of the Year 2004 Award for the Pacific Region Life Sciences Group and has received both Canada’s and British Columbia’s Top 40 Under 40 Award for Entrepreneurs.
Jackie M. Clegg (1)(2)
Director
Ms. Jackie Clegg currently serves as a Managing Partner of Clegg International Consultants, LLC. Ms. Clegg is a member of the board of directors of Javelin Pharmaceuticals, Inc., the Chicago Mercantile Exchange and Brookdale Senior Living. She is also on the board of Blockbuster Inc., where she serves as the Chair of the Corporate Governance Committee. She has served as the chair of special committees for divestiture, mergers and acquisitions. Previously, Ms. Clegg served in the U.S. Government. She served as Vice Chair of the Export-Import Bank of the U.S. (Ex-ImBank). Prior to joining Ex-ImBank, she served as a staff member on the U.S. Senate Committee on Banking International Finance Subcommittee and as an associate staff member to the U.S. Senate Committee on Appropriations.
William L. Hunter, M.D. (2)(3)
Director
Dr. Hunter is a co-founder of Angiotech Pharmaceuticals, Inc., and currently serves as President and Chief Executive Officer of the company. He has led Angiotech through significant corporate milestones from its initial rounds of private and public financings, to product commercialization and profitability. Active in a variety of business and scientific organizations, Dr. Hunter serves as the chair of the board for Neuromed Pharmaceuticals Ltd. He is an advisory board member for the Biotechnology MBA Program at the University of Western Ontario’s Ivey School of Business.
Peter W. Roberts, FCA, CPA (Illinois) (1)(2)
Director
Mr. Roberts retired as Chief Financial Officer and Corporate Secretary of Sierra Wireless, Inc. in March 2004. He served in this role from January 1999 until retirement, and was responsible for taking the company public on the Toronto Stock Exchange in May 1999 and a follow-on financing on NASDAQ in May 2000. Prior to joining Sierra Wireless, Inc., Mr. Roberts held senior financial roles over a fifteen-year period with Service Corporation IJK plc, The Loewen Group Inc., The Overwaitea and Save-On Foods Chain and Sydney Development Corporation. Mr. Roberts is a graduate of Touche Ross, and practiced a decade in public accounting. He holds professional accounting designations in Canada, the United States, and the United Kingdom. In June 2007, Mr. Roberts completed his term as President of the Institute of Chartered Accountants of British Columbia. Mr. Roberts is a member of the Risk Management and Governance Board of the Canadian Institute of Chartered Accountants, and is a graduate of the Institute of Corporate Directors.
Harold H. Shlevin, Ph.D. (1)(2)(3)
Director
Dr. Shlevin is the President & CEO of Tikvah Therapeutics, Inc., a pharmaceutical enterprise focused on late-stage development of compounds with strong intellectual property protection and significant market potential. Its primary development focus is on the novel application of existing therapeutic entities where clinical proof of concept is already well-established and its commercial focus is in the specialty areas of CNS psychiatry and neurology. Prior to this, Dr. Shlevin held the position of Global Senior Vice President, and a member of the boards of Solvay Pharmaceutical, SA and Solvay Pharmaceuticals Inc. He has also held a variety of other positions with Solvay Pharmaceuticals, including President & Chief Executive Officer of Solvay Pharmaceuticals US, and Senior Vice President of Business Development and Scientific Affairs. He was also a member of the management committee, an officer of the corporation, and Chairman of the Board of its independently owned and operated subsidiary, Unimed Pharmaceuticals, Inc. In addition to this, he was a member of the global pharmaceutical management committee for Solvay Pharmaceuticals Inc., the consortium of Solvay S.A worldwide pharmaceutical business, and a member of the board of Solvay Draka. Dr. Shlevin has almost three decades of diverse healthcare business-related experience, involving virtually every aspect of the pharmaceutical business from research and development to commercial operations. His past industry experience includes leadership roles at G.D. Searle and Co., Ciba-Geigy Corp. and he was a founder of Ciba Vision Opthalmics. Dr. Shlevin’s experience related to his responsibilities as an audit committee member include his tenure as CEO of Solvay and as Senior Vice President where he was regularly involved in assessments and analysis of financial statements and projections and acquisitions of companies and of products. Dr. Shlevin has also taken courses in financial strategies.
(1) Member of our Audit Committee
(2) Member of our Corporate Governance & Nomination Committee
(3) Member of our Compensation Committee